Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Sorrento is an Emerging BioPharma (EBP).By the end of this year Sorrento could have some 30 drugs in the clinic. Several in phase 3 and about a dozen in phase 2. In 2018 of the 59 new drugs approved seven approvals were based on phase 1 or phase 2 trials.
• Of the 59 new drug launches in 2018, 38 were patented by emerging biopharma companies, and 74% of those were also registered by these companies.
• Although the importance of large pharma in originating molecules is decreasing, they remain important partners for EBP companies even as EBP are increasingly able to commercialize alone.
• Large pharma companies registered nearly half of the new drugs in 2018, approximately half of which originated with emerging biopharma companies.

Anytime Sorrento chooses they can partner new drugs for upfront, milestone and royalty payments. OR they keep the worldwide rights and simply become a Big Pharma!
https://www.healthindustryhub.com.au/wp-content/uploads/2019/05/the-changing-landscape-of-research-and-development.pdf